EMC2

Across TCGA pan-cancer cohorts, EMC2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of EMC2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where EMC2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types EMC2 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

CCRCC, HNSC, and LUAD are the cancer types where EMC2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EMC2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−0.425	<.001	11	view →
HNSC	All	III,IV	+0.222	<.001	11	view →
LUAD	Female	II,III,IV	+0.227	<.001	8	view →
COAD	All	All	+0.074	.001	8	view →
LSCC	All	II,III,IV	+0.205	<.001	7	view →
PDAC	Male	All	+0.354	<.001	5	view →
OV	All	All	+0.243	.026	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

EMC2–CCRCC

Open the CCRCC breakdown →